Premium
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide
Author(s) -
Voskaridou Ersi,
Terpos Evangelos,
Komninaka Veroniki,
Eftyhiadis Eftyhios,
Mantzourani Marina,
Loukopoulos Dimitris
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03241.x
Subject(s) - anagrelide , thrombocytosis , leukocytosis , medicine , hydroxycarbamide , chronic myeloid leukaemia , myeloid , platelet , chromosomal translocation , breakpoint cluster region , gastroenterology , hematology , immunology , chemotherapy , essential thrombocythemia , biology , receptor , biochemistry , gene
Summary. The co‐existence of thalassaemia major and chronic myeloid leukaemia (CML) is a very rare event. We report a 32‐year‐old man with thalassaemia major whose progressively increasing leukocytosis and thrombocytosis led to the diagnosis of CML confirmed by the characteristic t(9;22)(q34;q11) chromosomal translocation and the bcr‐abl (b3a2) DNA fusion. The patient was treated with hydroxyurea and anagrelide. This combination resulted in the satisfactory control of both the white blood cell and platelet counts, which has continued over the past 14 months with no major side‐effects, albeit with no molecular response. The administration of hydroxyurea was also associated with a significant HbF increase.